In The News,
Gene Therapy Pricing
Identified policy and access strategies at the state and federal levels, commercial payers, and pricing that would maximize access – including bolstering arguments against any negative ICER or state-backed ICER review – after considering the payer mix, cost and clinical profiles of existing therapeutic alternatives, competitors, and potential tools Medicaid FFS, Medicaid health plans and commercial payers could use to negotiate pricing and restrict access for gene therapies delivered in the hospital and outpatient setting.